We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $9.59B
1-Year Est. Return 113.36%
This Fund
S&P 500
This Quarter Est. Return
-0.62%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$5.63B
AUM Growth
+$871M
Cap. Flow
-$403M
Cap. Flow %
-7.15%
Top 10 Hldgs %
32.98%
Holding
166
New
29
Increased
30
Reduced
12
Closed
23

Top Buys

Rank Stock Value
1
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$235M
2
AHCO icon
AdaptHealth
AHCO
+$145M
3
CMAX
CareMax, Inc. Class A Common Stock
CMAX
+$132M
4
ORGO icon
Organogenesis Holdings
ORGO
+$78.8M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$50.1M

Top Sells

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$110M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$88.6M
3
BIIB icon
Biogen
BIIB
+$86.7M
4
CNC icon
Centene
CNC
+$67.9M
5
STLN
Starling Oncology
STLN
+$55M

Sector Composition

Rank Sector Weight
1 Healthcare 69.33%
2 Miscellaneous 30.67%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CERT icon
126
Certara
CERT
$1.21B
– –
-600,000
Closed -$16.4M
ELVN icon
127
Enliven Therapeutics
ELVN
$4.35B
– –
-19,866
Closed -$671K
FDMT icon
128
4D Molecular Therapeutics
FDMT
$827M
– –
-150,000
Closed -$6.51M
GBIO
129
DELISTED
Generation Bio
GBIO
– –
-89,778
Closed -$25.6M
INNV icon
130
InnovAge Holding
INNV
$1.46B
– –
-300,000
Closed -$7.74M
PACB icon
131
Pacific Biosciences
PACB
$420M
– –
-468,000
Closed -$15.6M
SHC icon
132
Sotera Health
SHC
$5.39B
– –
-1,111,000
Closed -$27.7M
FTH
133
Faeth Therapeutics
FTH
$1.03B
– –
-18,750
Closed -$5.45M
STIM icon
134
Neuronetics
STIM
$219M
– –
-919,000
Closed -$11.4M
SYK icon
135
Stryker
SYK
$116B
– –
-59,000
Closed -$14.4M
WOOF icon
136
Petco
WOOF
$772M
– –
-500,000
Closed -$11.1M
GRCL
137
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
– –
-400,000
Closed -$6.16M
LABP
138
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
– –
-45,000
Closed -$4.33M
SGFY
139
DELISTED
Signify Health, Inc.
SGFY
– –
-400,000
Closed -$11.7M
RUBY
140
DELISTED
Rubius Therapeutics, Inc
RUBY
– –
-550,000
Closed -$14.6M
OCDX
141
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
– –
-2,352,941
Closed -$45.4M
HRC
142
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
– –
-279,870
Closed -$30.9M
ALXN
143
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-579,248
Closed -$88.6M
CAPAU
144
DELISTED
HighCape Capital Acquisition Corp. Unit
CAPAU
– –
-1,000,000
Closed -$12.9M
2 3 4 5
6

Similar funds

OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
MSE
MUFG Securities EMEA London, United Kingdom $9.53B AUM 52.96% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
A
Allianz Munich, Germany $9.48B AUM 23.58% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Deerfield Management's Q2 2021 Portfolio in Review

As of Q2 2021, Deerfield Management held 166 positions worth $5.63B, up 18% from $4.76B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Deerfield Management withdrew a net $403M in Q2 2021, closing 23 positions and reducing 12 holdings. Its most notable exit was Boston Scientific, an estimated $110M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 73% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

Against the trend, Deerfield Management opened a new position in Singular Genomics Systems, Inc. Common Stock worth $250M.

  • Deerfield Management's largest Q2 2021 buy was Singular Genomics Systems, Inc. Common Stock: 303,734 shares worth $250M.
  • Deerfield Management added most to AdaptHealth in Q2 2021, an estimated $145M increase.
  • Deerfield Management's biggest Q2 2021 reduction was Centene, cutting an estimated $67.9M.
  • Deerfield Management fully exited Boston Scientific in Q2 2021, selling an estimated $110M.
  • Deerfield Management's ten largest holdings make up 33% of its $5.63B portfolio in Q2 2021.
  • Deerfield Management opened 29 new positions and closed 23 in Q2 2021.
  • Deerfield Management's portfolio value rose 18% quarter-over-quarter to $5.63B.

Based on Deerfield Management's 13F filing for Q2 2021, filed 16 Aug 2021.